Endometrial hyperplasia prevention

Endometrial hyperplasia prevention describes clinical prophylactic management aimed at stopping the abnormal, non-physiologic proliferation of the uterine endometrium Prophylaxis counteracts this proliferative signaling by co-administering progestogens to induce secretory transformation, promote periodic shedding, and maintain normal endometrial architecture

Endometrial hyperplasia prevention describes clinical prophylactic management aimed at stopping the abnormal, non-physiologic proliferation of the uterine endometrium Pathophysiologically, sustained exposure to unopposed estrogen stimulates excessive mitotic activity in endometrial glandular epithelial cells, which increases the risk of architectural atypia, endometrial intraepithelial neoplasia, and subsequent progression to endometrioid adenocarcinoma

This preventive intervention primarily targets postmenopausal individuals with an intact uterus who are receiving exogenous systemic estrogen therapy for menopausal symptoms

This preventive intervention primarily targets postmenopausal individuals with an intact uterus who are receiving exogenous systemic estrogen therapy for menopausal symptoms

Pathophysiologically, sustained exposure to unopposed estrogen stimulates excessive mitotic activity in endometrial glandular epithelial cells, which increases the risk of architectural atypia, endometrial intraepithelial neoplasia, and subsequent progression to endometrioid adenocarcinoma

Prophylaxis counteracts this proliferative signaling by co-administering progestogens to induce secretory transformation, promote periodic shedding, and maintain normal endometrial architecture